Jostein Dahle
Nessuna posizione attualmente
Patrimonio netto: 20 449 $ in data 31/05/2024
Profilo
Jostein Dahle was the founder and had founded Nordic Nanovector ASA in 2009, where he held the title of Chief Scientific Officer.
He also worked as a Director at Oslo universitetssykehus HF.
Dr. Dahle has a doctorate degree from the University of Oslo, which he received in 2000, and a graduate degree from the Norwegian University of Science & Technology, which he received in 1995.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
THOR MEDICAL ASA
0.09% | 31/12/2022 | 212 191 ( 0.09% ) | 20 449 $ | 31/05/2024 |
Precedenti posizioni note di Jostein Dahle
| Società | Posizione | Fine |
|---|---|---|
Oslo universitetssykehus HF
 Oslo universitetssykehus HF Hospital/Nursing ManagementHealth Services Oslo universitetssykehus HF operates local hospital, acute hospitals, and regional hospital for residents and has a number of national tasks. It carries out patient treatment, research, and trial treatments, gives advice and provides education. The company was founded on December 1, 2008 and is headquartered in Oslo, Norway. | Direttore/Membro del Consiglio | - |
| THOR MEDICAL | Fondatore | - |
Formazione di Jostein Dahle
| University of Oslo | Doctorate Degree |
| Norwegian University of Science & Technology | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Nordic Nanovector ASA
 Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway. | Health Technology |
Oslo universitetssykehus HF
Oslo universitetssykehus HF Hospital/Nursing ManagementHealth Services Oslo universitetssykehus HF operates local hospital, acute hospitals, and regional hospital for residents and has a number of national tasks. It carries out patient treatment, research, and trial treatments, gives advice and provides education. The company was founded on December 1, 2008 and is headquartered in Oslo, Norway. | Health Services |
- Borsa valori
- Insiders
- Jostein Dahle
